↓ Skip to main content

American Association for Cancer Research

Article Metrics

Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia

Overview of attention for article published in Cancer Prevention Research, March 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 1,265)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
6 news outlets
blogs
4 blogs
twitter
11 tweeters
patent
1 patent
facebook
3 Facebook pages
video
6 video uploaders

Citations

dimensions_citation
355 Dimensions

Readers on

mendeley
284 Mendeley
Title
Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia
Published in
Cancer Prevention Research, March 2011
DOI 10.1158/1940-6207.capr-10-0098
Pubmed ID
Authors

Robert E. Carroll, Richard V. Benya, Danielle Kim Turgeon, Shaiju Vareed, Malloree Neuman, Luz Rodriguez, Madhuri Kakarala, Philip M. Carpenter, Christine McLaren, Frank L. Meyskens, Dean E. Brenner

Abstract

Curcumin is derived from the spice tumeric and has antiinflammatory and antineoplastic effects in vitro and in animal models, including preventing aberrant crypt foci (ACF) and adenomas in murine models of colorectal carcinogenesis. Inhibiting the production of the procarcinogenic eicosanoids prostaglandin E₂ (PGE₂) and 5-hydroxyeicosatetraenoic acid (5-HETE) can suppress carcinogenesis in rodents. Curcumin reduces mucosal concentrations of PGE₂ (via inhibition of cyclooxygenases 1 and 2) and 5-HETE (via inhibition of 5-lipoxygenase) in rats. Although preclinical data support curcumin activity in many sites, the poor bioavailability reported for this agent supports its use in the colorectum. We assessed the effects of oral curcumin (2 g or 4 g per day for 30 days) on PGE₂ within ACF (primary endpoint), 5-HETE, ACF number, and proliferation in a nonrandomized, open-label clinical trial in 44 eligible smokers with eight or more ACF on screening colonoscopy. We assessed pre- and posttreatment concentrations of PGE₂ and 5-HETE by liquid chromatography tandem mass spectroscopy in ACF and normal-tissue biopsies; ACF number via rectal endoscopy; proliferation by Ki-67 immunohistochemistry; and curcumin concentrations by high-performance liquid chromatography in serum and rectal mucosal samples. Forty-one subjects completed the study. Neither dose of curcumin reduced PGE₂ or 5-HETE within ACF or normal mucosa or reduced Ki-67 in normal mucosa. A significant 40% reduction in ACF number occurred with the 4-g dose (P < 0.005), whereas ACF were not reduced in the 2-g group. The ACF reduction in the 4-g group was associated with a significant, five-fold increase in posttreatment plasma curcumin/conjugate levels (versus pretreatment; P = 0.009). Curcumin was well tolerated at both 2 g and 4 g. Our data suggest that curcumin can decrease ACF number, and this is potentially mediated by curcumin conjugates delivered systemically.

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 284 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 1%
Canada 1 <1%
United Kingdom 1 <1%
Belgium 1 <1%
Brazil 1 <1%
Unknown 276 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 43 15%
Student > Bachelor 40 14%
Researcher 39 14%
Student > Ph. D. Student 29 10%
Other 25 9%
Other 59 21%
Unknown 49 17%
Readers by discipline Count As %
Medicine and Dentistry 68 24%
Agricultural and Biological Sciences 42 15%
Biochemistry, Genetics and Molecular Biology 33 12%
Pharmacology, Toxicology and Pharmaceutical Science 27 10%
Chemistry 15 5%
Other 43 15%
Unknown 56 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 84. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2021.
All research outputs
#355,391
of 20,083,595 outputs
Outputs from Cancer Prevention Research
#48
of 1,265 outputs
Outputs of similar age
#1,675
of 137,201 outputs
Outputs of similar age from Cancer Prevention Research
#1
of 48 outputs
Altmetric has tracked 20,083,595 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,265 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 137,201 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.